Molecular model of Imatinib (C29 H31 N7 O). Imatinib is part of a new class of drugs used in the treatment of chronic myelogenous leukaemia (CML), gastrointestinal stromal tumours (GIST) and a number of other malignancies. It acts by specifically inhibiting an enzyme (a receptor tyrosine kinase) that is characteristic of a particular cancer cell, rather than non-specifically inhibiting and killing all rapidly dividing cells. Carbon in grey; Hydrogen in white; Nitrogen in blue; Oxygen in red. Mol.
Model release not required. Property release not required.